Holen Sie sich die Stockscreener-App
0.00
2.94%
-0.102
Schlusskurs vom Vortag:
$0.102
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.62M
KGV:
0.00
EPS:
-244.2719
Netto-Cashflow:
$-17.61M
1W Leistung:
-2.94%
1M Leistung:
-22.22%
6M Leistung:
-74.07%
1J Leistung:
+623.57%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.00
Neximmune Inc Stock (NEXI) Company Profile
Compare NEXI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEXI
Neximmune Inc
|
0.00 | 0 | 0 | -20.62M | -17.61M | -244.27 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neximmune Inc Stock (NEXI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-01 | Eingeleitet | Raymond James | Outperform |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2021-03-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Neximmune Inc Aktie (NEXI) Neueste Nachrichten
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer - Bolsamania
NexImmune Inc stock (US65343B1044): Is its T-cell therapy platform strong enough to unlock biotech u - AD HOC NEWS
NexImmune Inc stock (US65343B1044): Is its T cell platform strong enough to unlock immunotherapy ups - AD HOC NEWS
NexImmune (NEXI) was downgraded to a Hold Rating at Citi - The Globe and Mail
Stock List: Research Stocks from Around the World - gurufocus.com
NexImmune Inc stock faces renewed scrutiny amid clinical trial updates and biotech sector volatility - AD HOC NEWS
NexImmune Inc stock faces renewed scrutiny amid biotech sector volatility and pipeline updates - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044): Immunotherapy Play Eyes Clinic Expansion Amid Biotech Vola - AD HOC NEWS
NexImmune Inc Stock (ISIN: US65343B1044) Faces Volatility Amid Biotech Sector Pressures - AD HOC NEWS
Nexi SpA (WBO:NEXI) NonCurrent Deferred Revenue : €0 Mil (As of Jun. 2025) - GuruFocus
NEXI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nexi SpA (MIL:NEXI) Capex-to-Revenue : 0.06 (As of Jun. 2025) - GuruFocus
Head-To-Head Comparison: Lunai Bioworks (NASDAQ:LNAI) vs. NexImmune (OTCMKTS:NEXI) - Defense World
Contrasting ASLAN Pharmaceuticals (NASDAQ:ASLN) & NexImmune (OTCMKTS:NEXI) - Defense World
NexImmune Inc Is Exploding Online – But Is NEXI Stock a Hidden Gem or a Total Trap? - AD HOC NEWS
The Truth About NexImmune Inc: Why Everyone Is Suddenly Watching This Micro-Cap Wildcard - AD HOC NEWS
NexImmune’s Vanishing Act: What Happens When a Ticker Survives but the Company Does Not? - AD HOC NEWS
Contrasting NexImmune (OTCMKTS:NEXI) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Critical Survey: Endonovo Therapeutics (OTCMKTS:ENDVD) & NexImmune (OTCMKTS:NEXI) - Defense World
NexImmune, Inc.Common Stock (NQ: NEXI - FinancialContent
NexImmune (NEXI) Insider Trading Activity 2026 - MarketBeat
Sinovac says co receives Nasdaq notification regarding late filing of 2025 half-year report - marketscreener.com
Critical Comparison: NexImmune (OTCMKTS:NEXI) & Antibe Therapeutics (OTCMKTS:ATBPF) - Defense World
NexImmune (NEXI) Short Interest & Short Float | Updated May 2026 - MarketBeat
NexImmune (NEXI) Stock Chart and Price History 2026 - MarketBeat
NexImmune (NEXI) 10K Form and SEC Filings 2026 - MarketBeat
NexImmune (NASDAQ:NEXI) Stock Price Up 2,169,900% – Here’s Why - Defense World
Blank check company Abony Acquisition Corp. I files for IPOSEC filing - marketscreener.com
NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison - Defense World
Blank check company Spartacus Acquisition Corp II files for IPO of 20 million units for $200 millionSEC filing - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - marketscreener.com
Vine Hill Capital Investment Corp. II Closes Initial Public Offering - marketscreener.com
Nasdaq Inc will be open as scheduled on Wednesday, December 24, 2025, and Friday, December 26, 2025 - marketscreener.com
Intellego board has asked Nasdaq to keep trading halted - marketscreener.com
Tradeweb CEO says round-the-clock trading to become mainstream - marketscreener.com
Alerts, brief on Cybin transferring US listing to Nasdaq withdrawn - marketscreener.com
Nasdaq sees bigger year ahead for listings on billion-dollar-plus IPOs - marketscreener.com
Ben strengthens balance sheet with over $1.24 million in liability reductions - marketscreener.com
Blank Check Co, Proem Acquisition Corp I files for IPO of up to $130 million - marketscreener.com
RTW Biotech invests USD5.9 million in Yarrow Bioscience funding round - marketscreener.com
Launchpad Cadenza Acquisition Corp I Prices IPO - marketscreener.com
SS Lazio, a global brand between the stock market and US ambitions - marketscreener.com
Wall St slips on losses in healthcare and energy stocks; focus on economic data - MarketScreener
Nasdaq seeks to extend trading hours to nearly round-the-clock - marketscreener.com
Bitcoin hoarding company Strategy remains in Nasdaq 100 - marketscreener.com
Nasdaq submits new plan with more power to block IPOs vulnerable to manipulation - marketscreener.com
Nasdaq seeks more power to block IPOs vulnerable to manipulation - marketscreener.com
Critical Survey: NexImmune (NASDAQ:NEXI) and Palatin Technologies (PINK:PTNT) - Defense World
Critical Review: NexImmune (NASDAQ:NEXI) and Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
NexImmune (NASDAQ:NEXI) versus iBio (NYSE:IBIO) Financial Survey - Defense World
Head-To-Head Survey: NexImmune (NASDAQ:NEXI) versus Evotec (OTCMKTS:EVTCY) - Defense World
Finanzdaten der Neximmune Inc-Aktie (NEXI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
Kapitalisierung:
|
Volumen (24h):